The acronym decoder: speaking pharma fluently

From WAC, subtract GTN (Gross-to-Net): the umbrella term for all the deductions between list price and net revenue, rebates to insurers and Pharmacy Benefit Managers (PBMs, the middlemen who negotiate formulary placement), discounts to wholesalers, copay assistance, government mandated rebates (Medicaid in the US), and returns.

What's left is net price, the actual revenue per unit a company reports. For many branded US drugs, net price runs 40 to 60% of WAC as a rough estimate; for some heavily rebated categories (insulins, for instance, before recent list-price cuts), the gap has historically been even wider. This is company- and drug-specific and changes yearly, so treat any single percentage as illustrative, not universal.

ASP (Average Sales Price) is a related but distinct US Medicare concept: the actual average price paid for a drug net of most rebates, used specifically to set Medicare Part B reimbursement for physician-administered drugs (think infused cancer therapies). ASP is recalculated quarterly and reported to CMS (the Centers for Medicare & Medicaid Services).

Worked example:

• WAC per unit: $1,000
• GTN deduction: 50% (a mid-range illustrative assumption)
• Net price: $500
• If the company sells 2 million units in a quarter, gross WAC-equivalent sales look like $2 billion, but reported net revenue is $1 billion.

This is why headline "list price" stories in the press routinely overstate what a pharma company actually earns.

Tracking demand before it's revenue: NBRx and TRx

Before any of that revenue shows up in an earnings report, analysts watch prescription data, usually sourced from IQVIA, the dominant data provider in pharma commercial analytics.

• NBRx (New-to-Brand prescriptions): a patient starting on this specific drug for the first time. This is the leading indicator of a launch's health, it reflects new doctor decisions today.
• TRx (Total prescriptions): all prescriptions filled, new and refills combined. This is the lagging, steadier indicator of installed base.
• NRx is sometimes used interchangeably with NBRx or to mean "new prescriptions" more broadly; always check how a specific company defines it in its disclosures.

When a CFO says "NBRx trends were soft," they mean new patient starts are slowing, a warning sign that shows up in prescription data weeks before it shows up in revenue.

Regulatory and market-access acronyms you'll hear constantly

• FDA: US Food and Drug Administration, approves drugs for the US market.
• EMA: European Medicines Agency, coordinates approval recommendations across the EU (individual reimbursement decisions remain national).
• PBM: Pharmacy Benefit Manager (e.g., CVS Caremark, Express Scripts, Optum Rx), negotiates formulary placement and rebates in the US, controls what patients actually pay at the pharmacy counter.
• HTA: Health Technology Assessment, the process European bodies (like Germany's IQWiG or the UK's NICE) use to decide if a drug's price is justified by its clinical benefit, effectively gatekeeping reimbursement.
• IRA: Inflation Reduction Act (US, 2022), gives Medicare negotiating power over select drug prices for the first time and caps some out-of-pocket costs; its price effects are still phasing in through the mid-2020s.
• LOE: Loss of Exclusivity, the point a branded drug's patent protection ends and generic or biosimilar competition enters, often causing 70 to 90% volume/revenue erosion within a year or two, a well-documented industry pattern sometimes called the "patent cliff."

Market size: the numbers to anchor on

As rough, widely cited estimates (treat as approximate, figures shift year to year and by source methodology):

• US pharmaceutical market: roughly $600 to $650 billion in annual net spending as of the mid-2020s, per estimates from IQVIA Institute reports, the single largest national market and the most profitable due to relatively freer pricing.
• Europe (major five: Germany, France, Italy, Spain, UK): combined market meaningfully smaller than the US, generally estimated in the $150 to 200 billion range, with per-country pricing set through national HTA and negotiation processes rather than a single EU price.
• Global pharma market: commonly estimated around $1.6 to $1.8 trillion as of the mid-2020s (IQVIA and EvaluatePharma-type estimates), growing roughly mid-single digits annually, driven heavily by oncology, immunology, and obesity/metabolic drugs.

The US-Europe price gap is structural, not incidental: the US has no central price negotiator (historically), while most European systems price drugs relative to clinical benefit through HTA before granting reimbursement. This is the single biggest reason identical drugs earn dramatically different net prices across the Atlantic.

The due-diligence checklist: what practitioners actually check

When evaluating a pharma company or a specific drug's commercial story, professionals routinely check:

1. NBRx trajectory, not just TRx. Total prescriptions can look stable while new patient starts are quietly collapsing, masking a coming decline.

2. GTN trend direction. Rising GTN deductions (expanding rebates) erode net price even if gross WAC and volumes look fine, a common way headline "growth" hides margin compression.

3. Patent expiry dates and LOE timing. Check a drug's exclusivity status via the FDA's Orange Book or the EMA's equivalent listings, this tells you how many years of protected revenue remain.

4. Payer mix and formulary tier. A drug placed on a restrictive PBM formulary tier faces higher copays and lower uptake regardless of clinical quality.

5. HTA outcomes in Europe. A NICE or IQWiG rejection (or a restrictive reimbursement label) can eliminate a market even after EMA approval, approval and reimbursement are two separate battles.

🎬 [VIDEO: "How Drug Pricing Actually Works in the US" - youtube.com - search for recent explainer content from health policy channels like Peterson-KFF or Healthcare Triage covering WAC, rebates, and PBMs in plain language]

Key Takeaways

• WAC minus GTN equals net price: the gap between pharma list prices and actual revenue is the single most misunderstood number in the sector, often 40 to 60%+ as a rough, variable estimate.
• NBRx leads, TRx lags: watch new-patient prescription trends to spot a launch's real momentum before it appears in reported revenue.
• US and Europe are structurally different markets: the US (roughly $600 to 650 billion, estimate) prices more freely; Europe (roughly $150 to 200 billion combined across major markets, estimate) prices through HTA-driven negotiation, producing persistently lower net prices.
• LOE is the biggest single risk factor in any drug-level analysis, check exclusivity timelines via the Orange Book or EMA data before trusting a multi-year revenue forecast.
• Approval is not reimbursement: FDA or EMA clearance only opens the door; PBM formulary status (US) or HTA verdicts (Europe) determine whether patients can actually access, and companies can actually monetize, a drug.